摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,4-dimethyl-6-heptyn-2-one | 17520-15-9

中文名称
——
中文别名
——
英文名称
4,4-dimethyl-6-heptyn-2-one
英文别名
4,4-dimethylhept-6-yn-2-one
4,4-dimethyl-6-heptyn-2-one化学式
CAS
17520-15-9
化学式
C9H14O
mdl
——
分子量
138.21
InChiKey
PXIVGHUHGWWZJQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    75-80 °C(Press: 14 Torr)
  • 密度:
    0.874±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    10
  • 可旋转键数:
    3
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.67
  • 拓扑面积:
    17.1
  • 氢给体数:
    0
  • 氢受体数:
    1

SDS

SDS:33f5973172e5b73d297c095512c9aa08
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    Silyl-cupration of an acetylene followed by ring-formation
    摘要:
    烷炔1a–e经历硅烷-铜化反应后进行环化,而烷炔1f–1h在另一种电亲和位点与硅烷-铜试剂的反应速度更快,烷炔1i、1j和17等反应给出的环状产物产率相对较低。环的形成在这里是不太常见的,不是特别有利的途径。
    DOI:
    10.1039/a809813a
  • 作为产物:
    描述:
    二苯醚 为溶剂, 以84%的产率得到4,4-dimethyl-6-heptyn-2-one
    参考文献:
    名称:
    Isotope effects and the mechanism of fragmentation of epoxy imino-1,3,4-oxadiazolines
    摘要:
    The fragmentation of an epoxy imino-1,3,4-oxadiazoline is studied by a combination of isotope effects and theoretical calculations. Significant primary C-13 isotope effects are observed at the two oxadiazoline carbons but negligible isotope effects are observed at the remaining carbons. This is consistent with a rate-limiting fragmentation of the oxadiazoline without fragmentation of the adjacent epoxide ring. Theoretical calculations support this interpretation. This formal coarctate reaction avoids two complicated coarctate fragmentations in favor of a multi-step mechanism with a simple coarctate final step. (C) 2004 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.tetlet.2004.12.008
点击查看最新优质反应信息

文献信息

  • Synthesis of trifluoromethylated isoxazoles and their elaboration through inter- and intra-molecular C–H arylation
    作者:Jian-Siang Poh、Cristina García-Ruiz、Andrea Zúñiga、Francesca Meroni、David C. Blakemore、Duncan L. Browne、Steven V. Ley
    DOI:10.1039/c6ob00970k
    日期:——
    conditions for the preparation of a range of trifluoromethylated isoxazole building blocks through the cycloaddition reaction of trifluoromethyl nitrile oxide. It was found that controlling the rate (and therefore concentration) of the formation of the trifluoromethyl nitrile oxide was Critical for the preferential formation of the desired isoxazole products versus the furoxan dimer. Different conditions were
    我们报告了通过三氟甲基腈的环加成反应制备一系列三氟甲基化的异恶唑结构单元的条件。已发现控制三氟甲基丁腈氧化物的形成速率(以及浓度)对于优先形成所需的异恶唑产物比呋喃二聚体。针对芳基和烷基取代的炔烃优化了不同的条件。此外,已针对这些结构单元简要探讨了异恶唑4位的反应性。分子间CH-H芳基化,锂化和亲电淬灭以及烷氧基化的条件均通过简短的底物作用域确定,这表明对一系列功能的有用耐受性。最后,开发了通过分子内环化或分子间交叉偶联进行结构多样化的互补过程。
  • Synthesis of functionalised cyclopentanes by intramolecular radical-mediated cyclisations of terminal allenic ketones
    作者:Gerald Pattenden、Graeme M. Robertson
    DOI:10.1016/s0040-4020(01)97179-0
    日期:1985.1
    Electrolysis of a series of terminal allenic ketones e.g. (7), (10), (17) and (21) is shown to result in intramolecular reductive cyclisation, through the -mode, producing five-membered rings, (8), (9), (20) and (22) respectively, incorporating a bridgehead hydroxyl group. The unsaturated alcohols (8), (20) and (22), are also obtained when the allenic ketones (7), (17) and (21) are treated with sodium
    一系列末端烯丙基酮如(7),(10),(17)和(21)的电解显示通过-模式导致分子内还原环化,产生五元环(8),(9) ),(20)和(22)分别掺入桥头羟基。当用萘二甲酸钠处理烯丙基酮(7),(17)和(21)时,也获得不饱和醇(8),(20)和(22)。相反,通过在-模式下环化,在萘钠中的(10)处理产生低产率(7%)的异构体茚满醇(11)。
  • A Versatile Route to Unstable Diazo Compounds via Oxadiazolines and their Use in Aryl-Alkyl Cross-Coupling Reactions
    作者:Andreas Greb、Jian-Siang Poh、Stephanie Greed、Claudio Battilocchio、Patrick Pasau、David C. Blakemore、Steven V. Ley
    DOI:10.1002/anie.201710445
    日期:2017.12.22
    Coupling of readily available boronic acids and diazo compounds has emerged recently as a powerful metal-free carbon-carbon bond forming method. However, the difficulty in forming the unstable diazo compound partner in a mild fashion has hitherto limited their general use and the scope of the transformation. Here, we report the application of oxadiazolines as precursors for the generation of an unstable
    作为一种有效的无金属碳-碳键形成方法,最近出现了易于获得的硼酸和重氮化合物的偶联。然而,迄今为止,以温和的方式形成不稳定的重氮化合物伴侣的困难限制了它们的一般用途和转化范围。在这里,我们报道了恶二唑啉作为前体的应用,它使用流式紫外光解法生成不稳定的重氮化合物家族,并首次用于不同的原去硼和氧化C(sp2)-C(sp3)交叉偶联过程中,具有出色的功能组容忍度。
  • Mixed Phosphane η<sup>5</sup>-CpRuCl(PR<sub>3</sub>)<sub>2</sub>Complexes as Ambifunctional Catalysts for Anti-Markovnikov Hydration of Terminal Alkynes
    作者:Florian Boeck、Thomas Kribber、Li Xiao、Lukas Hintermann
    DOI:10.1021/ja2026823
    日期:2011.6.1
    at C-6) for anti-Markovnikov hydration of terminal alkynes to aldehydes is retained when one heterocyclic ligand L is replaced by L' = PPh(3). Equal amounts of CpRuCl(PPh(3))(2) (1) and phosphane L in acetone solution equilibrate to a mixture of 1, CpRuCl(L)(PPh(3)) (2), and CpRuCl(L)(2) (3), which acts as highly active in situ catalyst for preparative anti-Markovnikov hydration of alkynes in water-rich
    [CpRu(L)(2)(MeCN)]PF(6)(L = 2-diphenylphosphinopyridine 在 C-6 处具有庞大的基团)在一个杂环配体时保留了对末端炔烃的反马尔科夫尼科夫水合反应的催化活性L 由 L' = PPh(3) 代替。丙酮溶液中等量的 CpRuCl(PPh(3))(2) (1) 和磷烷 L 平衡为 1、CpRuCl(L)(PPh(3)) (2) 和 CpRuCl(L)(2) 的混合物) (3),在富水介质(2 mol % [Ru],60 °C,3-18 h in 4:1 (v/v ) 丙酮/水)。反应在 160 °C 下 <15 分钟内完成。
  • [EN] HSP-90 BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE FN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES<br/>[FR] COMPOSÉS SE FIXANT À LA HSP-90, COMPOSITIONS DE CEUX-CI ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES AUTO-IMMUNES ET INFLAMMATOIRES
    申请人:AEGERA THERAPEUTICS INC
    公开号:WO2011035417A1
    公开(公告)日:2011-03-31
    The invention relates to therapeutic compounds that bind to HSP90. The compounds disclosed herein bind HSP90 and alter the chaperoning capability of HSP90 proteins. The invention also relates to pharmaceutical compositions comprising these compounds, and methods of treating diseases and disorders such as cancer, autoimmune disease and other diseases.
    这项发明涉及与HSP90结合的治疗化合物。本文所披露的化合物与HSP90结合并改变HSP90蛋白的分子伴侣能力。该发明还涉及包含这些化合物的药物组合物,以及治疗癌症、自身免疫疾病和其他疾病的方法。
查看更多